Document Detail

Etanercept for refractory asthma therapy.
MedLine Citation:
PMID:  16989602     Owner:  NLM     Status:  MEDLINE    
Asthma is a chronic disease of the airways in which inflammation causes bronchial hyper-reactivity and consequent asthma attacks triggered by various stimuli. The bronchospasm attacks are usually relieved by short-acting beta2 agonists, and inflammation and bronchial hyper-reactivity are reduced by maintenance therapy and, in particular, by inhaled corticosteroids. In milder asthma subjects, airway inflammation is dominated by eosinophils, whereas in more severe asthma increased neutrophil counts were detected. In severe/refractory asthma, TNF-alpha is known to play a role in the maintenance of neutrophilic inflammation and of bronchial hyper-responsiveness and is not influenced by corticosteroid therapy. Etanercept, a TNF-alpha-blocking agent, could represent one of the potential therapies for refractory asthma based on demonstrated safety and efficacy.
Sabina A Antoniu
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  15     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-09-22     Completed Date:  2006-11-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  1279-81     Citation Subset:  IM    
Clinic of Pulmonary Disease, 30 Dr I Cihac Street, 700115 Iasi, Romania.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Asthmatic Agents / therapeutic use*
Asthma / drug therapy*,  immunology,  pathology,  physiopathology
Immunoglobulin G / therapeutic use*
Receptors, Tumor Necrosis Factor / therapeutic use*
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Reg. No./Substance:
0/Anti-Asthmatic Agents; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 185243-69-0/TNFR-Fc fusion protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Aliskiren: a renin inhibitor offering a new approach for the treatment of hypertension.
Next Document:  7th EFIS Tatra Immunology Conference. Molecular determinants of T-cell immunity. 24-28 June 2006, Hi...